InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) has closed a research and development contract with ATERA SAS of France, a key tissue engineering entity specializing in the advancement of innovative human tissue models.
The buzz
Under the terms of the finalized contract, ATERA will work on 3D human skin models of EB to evaluate the in vitro drug efficacy of firm’s key compound named INM-750, a topical Cannabinoid product candidate planned as a therapy for EB and also for other prospective wound-healing as well as dermatological applications. InMed reported that ATERA will evaluate the beneficial impacts of topically applied “INM-750” at ultra-structural molecular as well as cellular levels on in-vitro 3D remodeled full thickness skin models made of EB-derived as well as normal skin cells.
Dr. Sazzad Hossain, who is the CSO of InMed, posted that INM-750 has shown notable potential in pre-clinical prototypes to resolve symptomatic improvement of EB, which also includes wound healing and drop in pain, itch and inflammation. This contract with ATERA is intended to evaluate the prospect of INM-750 to consider disease reversal, further advancing firm’s existing data exhibiting an up-regulation in specific keratins in the skin.
By applying full-thickness skin models received from EB skin samples, the team can enhance overall efficacy and target effect of INM-750 in vitro ahead of firm’s imminent clinical study plan. Bart De Wever, who is the CEO of ATERA, posted that producing 3D human tissue mechanisms of specific ailments in a restricted, reproducible way gives a unique tool for drug advancement screening.
Read More